INVEST IN EO2 CONCEPTS TODAY!
Oxygen-Enhanced Technology for Advanced Wound Healing and Skin Support
$418,733.68 Raised
REASONS TO INVEST
EO2’s CDO therapy system is an enhanced wound care solution that improves patient outcomes when recovering from chronic wounds, skin injuries, or surgeries. It utilizes the continuous delivery of oxygen directly to the tissue, which has been shown to achieve faster healing, reduced pain levels, and overall improved skin health.*
EO2’s addressable market encompasses two multibillion dollar divisions. Globally, the chronic wound care sector is estimated to be worth over $20B,*while the aesthetics and cosmetic surgery industry is valued at $63.4B and expected to exhibit nearly double digit CAGR between now and 2030.*
As an industry innovator, EO2 is focused on continual product testing, research, development, and design, in collaboration with key opinion leaders and medical professionals. Our unique position in an expanding marketplace is secure through 2038, protected by numerous national and international patents, as well as additional patents pending.
*Market information provided by (source) (source) (source)
overview
Advanced Wound Care Therapy Powered By Pure Oxygen
For patients recovering from wounds (i.e. ulcers and burns), amputations, and cosmetic/restorative surgeries, oxygen is one of the most vital elements in the wound-healing process (source). Understanding this, EO2 has developed proprietary technology that allows pure, humidified oxygen to be continuously diffused directly into the tissue, thereby creating an optimal environment for skin repair and restoration. The OxyGeni is an all-inclusive system that offers oxygen generation, wound monitoring, oxygen diffusion dressings, and accessories, all in one lightweight and discrete wearable device.
The Problem & Our Solution
Making CDO Therapy Accessible To Support Wound Healing 24/7
A common obstacle to proper healing of wounds is a lack of oxygen, caused by blocked or damaged blood pathways. Oxygen via the bloodstream is what provides nourishment to the skin and dermal tissues, fueling important processes like collagen formation, cellular regeneration, antibacterial activity, and repair. When the body doesn’t have access to sufficient levels of oxygen, it becomes much harder to carry out these essential functions. However, most existing wound care options involve covering damaged skin, thereby blocking direct flow of oxygen to the tissue.
As a solution, EO2 has developed a system that not only restores oxygen levels, yet also enhances those levels beyond the body’s normal capacity. Using our wearable device, patients receive advanced wound care anywhere, anytime, and are able to accelerate the entire healing process. Additionally, because CDO therapy has benefits for reducing pain and inhibiting the formation of scars, the technology helps to restore quality of life. Positive outcomes from treatment with OxyGeni range from improving aesthetic appearance to preventing amputation.
The Market & Our Traction
Building a Science-Backed Brand That’s Responsive To An Evolving Market
Over the last several years, EO2 has been making significant progress across many verticals. In clinical trials, the company’s technology has been substantiated by multiple studies, with peer-reviewed papers published by notable national and international industry leaders. Meanwhile, on the marketing side, we’ve seen mass social media response to the performance of our products for patients, especially in the cosmetic procedures market.
As a result of our success in these areas, EO2 has seen a robust increase in sales. Within the plastics and aesthetics market, we’ve demonstrated triple-digit YOY growth and in Canada, the company has moved from unpaid trials to payment models in six provinces. By creating products designed to accommodate today’s telehealth models, we are enabling patients to be more involved in their own care through mobile app design, automated product delivery, and AI-driven communication.
Although EO2 Concepts initially developed solutions for the chronic wound care market, the company has exciting opportunities to expand into other markets based on the science of oxygen therapy’s efficacy and the feedback of medical users. Our newest and fastest-growing market is in aesthetic and reconstructive surgery, as the technology can be used to facilitate healing following face lifts, breast reductions, laser facials, and cosmetic injectables.
Why Invest
Invest in Proven Technology That Helps People Heal
Chronic wounds affect millions of patients each year and the costs to our healthcare system for diabetic foot complications alone are comparable to all cancers combined (source). Complications from a wound can last months or years, sometimes resulting in amputations, and severely impacting quality of life for patients. Having developed a system that can improve recovery outcomes, in a more accessible and affordable format, EO2’s vision is to bring our technology to the medical community and become the standard of care across multiple segments. Be a part of our success story by investing on Start Engine!
ABOUT
HEADQUARTERS
12500 Network Blvd Ste 310
San Antonio, TX 78249
WEBSITE
View Site
EO2 Concepts is an advanced wound healing technology company leveraging continuous diffusion of oxygen (CDO) therapy to commercialize innovative medical modalities. The company’s primary in-market product is OxyGeni, a wearable device designed to heal wounds to complete closure while simultaneously supporting skin and soft tissue restoration, shortening recovery time, reducing pain, and minimizing the formation of scar tissue in the process.
TEAM
Mark Niederauer
President, CEO, Board Member
Dave Kazynski
Exec. VP of Sales and Marketing, Board Member
Peter Smith
Chairman of the Board of Directors
Jim Walsh
Board of Directors Member
Jim DeYoung
Board Member
Justin Cypert
Controller
James P. Daley
Director of Operations
Cyndi Gilliam, BSN, RN, FACCWS
Director of Clinical Affairs
Kate Biasiolli
Marketing Manager
Joseph Monosmith
Quality Assurance Manager
TERMS
EO2 Concepts
Overview
PRICE PER SHARE
$1.59
DEADLINE
Apr 11, 2023
VALUATION
$78.44M
AMOUNT RAISED
$418,733.68
Breakdown
MIN INVESTMENT
$298.92
MAX INVESTMENT
$1,234,997.52
MIN NUMBER OF SHARES OFFERED
9,433
OFFERING TYPE
Equity
ASSET TYPE
PREFERRED
SHARES OFFERED
Series A Non-Voting Preferred Stock
MAX NUMBER OF SHARES OFFERED
776,728
Maximum Number of Shares Offered subject to adjustment for bonus shares
Company | : | Electrochemical Oxygen Concepts, Inc. |
Corporate Address | : | 12500 Network Blvd Ste 310, San Antonio, TX 78249 |
Offering Minimum | : | $14,998.47 |
Offering Maximum | : | $1,234,997.52 |
Minimum Investment Amount(per investor) | : | $297.04 |
Terms
Offering Type | : | Equity |
Security Name | : | Series A Non-Voting Preferred Stock |
Minimum Number of Shares Offered | : | 6,290 |
Maximum Number of Shares Offered | : | 776,728 |
Price per Share | : | $1.59 |
Pre-Money Valuation | : | $78,442,740.32 |
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
Time Based Perks
o First 72 hours – 10% Super Early Bird Bonus
o First week (days 4-7) – 8% Very Early Bird Bonus
o First 3 weeks (week 2 & 3) - 5% Early Bird Bonus
Amount Based Perks
o $600+ – 3% bonus shares , Member, Contributing to enabling advanced healing with oxygen.
o $1,500+ – 5% bonus shares, Leader, Leading the way in oxygen healing solutions.
o $5,000+ – 8% bonus shares, Innovator, Bringing next generation solutions to oxygen delivery and patient monitoring.
o $15,000+ – 10% bonus shares, Visionary, Ensuring the long-term growth and innovation in oxygen solutions for health care.
Loyalty Bonus - 10% Bonus Shares for Friends and Family
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Electrochemical Oxygen Concepts, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series A Non-Voting Preferred Stock at $1.59/ share, you will receive 110 shares of Series A Non-Voting Preferred Stock, meaning you'll own 110 shares for $159. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and an the Loyalty bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
The Company will not incur irregular use of proceeds.
NEW UPDATES
03.21.23
400K Fundraising Milestone Reached!
Another fundraising milestone met this week! We have now passed $400k and are approaching $450k. If you haven’t had a chance, please take a moment to check out our investment opportunity on StartEngine.
Click on the link to learn more and join us! - https://www.startengine.com/offering/eo2
PRESS
ALL UPDATES
03.17.23
New Patent Expanding EO2's Protection Through 2038!
We've had an exciting week at EO2! We were issued our seventh US Patent (patent number 11,529,503). This patent expands on the use of CDO with signals from the wound bed, allowing for wound bed monitoring and adjustments to therapy based on those signals. This patent allowance also expands on the growing number of US and International Patents that provide core patent protection through 2038.
We are excited about the security this brings to the future of CDO Therapy. To learn more or join us, go to: https://www.startengine.com/offering/eo2
02.28.23
350K Fundraising Milestone Reached!
We are excited to have reached another fundraising milestone this week! We have now passed $350k and are approaching $400k. If you haven’t had a chance, please take a moment to check out our investment opportunity on StartEngine.
Click on the link to learn more and join us! - https://www.startengine.com/offering/eo2
02.24.23
Another Goal Down: 250K Reached!
Another fundraising goal reached! We have now passed $250k and are approaching $300k. If you haven’t had a chance, please take a moment to check out our investment opportunity on StartEngine.
Click on the link to learn more and join us! - https://www.startengine.com/offering/eo2
02.23.23
Patient Off Pain Meds in 4 Days After Major Abdominal Surgery
In our latest webinar, Rechelle Trejo, RN describes her personal experience using CDO Therapy for 2 of her own elective surgeries. Rechelle presents her photos and experience after a Lateral Brow Lift where she experienced minimal bruising, no pain and minimal scarring. After her major Abdominalplasty, she was off pain medication within 4 days.
Listen to Rachelle's full experience here:
Click on the link to learn more and join us! - https://www.startengine.com/offering/eo2
02.15.23
Baylor Study Results: Reduced Wound Size & Increased Tissue Oxygenation for Breast Surgery with CDO
The first results from a Baylor College of Medicine mammoplasty study were presented last week at the 18th Annual Academic Surgical Congress at Baylor College of Medicine. The findings showed that compared to the current standard of care, CDO reduces wound size and significantly increases tissue oxygenation for women undergoing breast surgery.
Clinically these findings would mean a reduction in complications from breast surgeries, which in turn would increase patient satisfaction and save money by minimizing potential revision surgeries.
Excited to see results to even more of the ongoing clinical studies we have! See this study's details here: https://eppro01.ativ.me/web/page.php?page=Inthtml&project=ASC23&id=03.23
02.09.23
Another Goal Met: Approaching $250k!
We are excited to have reached another fundraising goal! We have now passed $200k and are quickly approaching $250k. If you haven’t had a chance yet, please take a moment to check out our investment opportunity on StartEngine.
Click on the link to learn more and join us! - https://www.startengine.com/offering/eo2
02.06.23
Notice of Material Change in Offering
[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the EO2 Concepts offering. Here's an excerpt describing the specifics of the change:
Campaign is extending their end date by 60 days
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
01.27.23
EO2’s International Sales Team Plans for 2023!
Our International Sales Team met this week to exchange ideas and plans for growth in 2023. We had 2 full days packed with exciting ideas. Looking forward to the success for this new year with this team.
To join our team in our future endeavors and learn more, go to: https://www.startengine.com/offering/eo2
01.17.23
American Diabetes Association recommends CDO Therapy as a “Standard of Care” for the treatment of Diabetic Foot Ulcers
The American Diabetes Association (ADA) regularly publishes standards of care and has just added CDO Therapy to their 2023 Standards of Care for the treatment of diabetic foot ulcers. The ADA article cites recent high level evidence for this decision:
“Topical oxygen therapy has been studied rather vigorously in recent years, with several high-quality RCT’s and at least five systematic reviews and meta-analyses all supporting its efficacy in healing chronic DFU’s at 12 weeks.” Diabetes Care, Volume 46, p. S212, January 2023. https://doi.org/10.2337/dc23-S012
This evidence includes EO2’s study published in the September of 2018 issue of the Journal of Wound Care, cited by CMS as the “Gold Standard” for how studies should be designed.
The ADA Standards of Care article goes on to state:
“Importantly, topical oxygen therapy devices provide for home-based therapy rather than the need for daily visits to specialized centers.” (such as Hyperbaric Oxygen) “Very high participation with very few reported adverse events combined with improved healing rates makes this therapy another attractive option for advanced wound care.”
The physicians who have experienced the significant impact of CDO therapy, including faster healing, reduced scarring and pain, have known that this treatment should be considered the standard of care for most wound types. Having an independent, clinically oriented organization like the American Diabetes Association make the same recommendation highlights the not only the clinical efficacy, yet also the rapidly growing adoption of CDO therapy as a standard of care.
To learn more and join us, go to: https://www.startengine.com/offering/eo2
01.10.23
Behind the Scenes at EO2!
The holidays have ended, and everyone is getting back in the swing of things at EO2. Did you know that EO2 manufactures our own wound dressings and the OxyGeni device? One of our manufacturing technicians, Sisee, is shown here punching tubing, one of the first steps in our dressing assembly.
To join our team in our future endeavors and learn more, go to: https://www.startengine.com/offering/eo2
Stack Owner's Bonus & Rewards!
Members get an extra 10% shares in addition to rewards below!
REWARDS
$298
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$600
Member
Invest $600+ and receive 3% Bonus shares
$1,500
Leader
Invest $1,500+ and receive 5% Bonus shares
$5,000
Innovator
Invest $5,000+ and receive 8% Bonus shares
$15,000
Visionary
Invest $15,000+ and receive 10% Bonus Shares
JOIN THE DISCUSSION
0/2500
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
